A double blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-00915275 [PF-915275] after oral administration to subjects with type 2 diabetes mellitus for 4 weeks

Trial Profile

A double blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-00915275 [PF-915275] after oral administration to subjects with type 2 diabetes mellitus for 4 weeks

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2008

At a glance

  • Drugs PF 915275 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jan 2008 Status changed from in progress to discontinued according to ClinicalTrials.gov.
    • 17 Aug 2007 Status changed from recruiting to in progress.
    • 20 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top